We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PolyTherics is Granted a Further Patent for its TheraPEG™ PEGylation Technology
Product News

PolyTherics is Granted a Further Patent for its TheraPEG™ PEGylation Technology

PolyTherics is Granted a Further Patent for its TheraPEG™ PEGylation Technology
Product News

PolyTherics is Granted a Further Patent for its TheraPEG™ PEGylation Technology


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PolyTherics is Granted a Further Patent for its TheraPEG™ PEGylation Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PolyTherics Limited, has announced that a further patent has been issued by the US Patent Office for TheraPEG™, PolyTherics’ proprietary method of improving the pharmacokinetic properties of proteins and peptides.

The patent consolidates PolyTherics’ TheraPEG™ patent portfolio, which covers proteins PEGylated using TheraPEG™, the reagents and the conjugation process.

PolyTherics has successfully applied its TheraPEG™ technology to a range of proteins and peptides, including interferons, blood factors and a variety of antibody formats.

The latter include antibody fragments (Fabs), single chain antibodies (scFv) and novel entities such as MacroGenics’ Dual-Affinity Re-Targeting molecules (DART™).

Nuron Biotech Inc has recently announced an exclusive option and license agreement with PolyTherics to use TheraPEG™ to develop NU400, a long-acting version of its proprietary recombinant human interferon beta-1b, which could enter the clinic in 2012 for the treatment of multiple sclerosis.

John Burt, CEO of PolyTherics commented “We are pleased that our TheraPEG™ patent estate has been further extended in the US with this second US patent, which strengthens our position in offering a solution for proteins and peptides in need of half-life extension. Licensees of PolyTherics’ TheraPEG™ technology will enjoy the benefit of the additional patent protection for their products developed using the TheraPEG™ technology”.

Advertisement